Poliovirus antigenic hybrids simultaneously expressing antigenic determinants from all three serotypes.

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• Poliovirus (PV) exists in three serotypes, posing a continuous public health challenge.
• Antigenic sites on the poliovirus capsid are critical for serotype-specific neutralization and vaccine development.

Purpose of the Study:

• To construct and characterize hybrid polioviruses (PVs) expressing antigenic determinants from PV type 2 and type 3 on a PV type 1 (Mahoney) capsid.
• To investigate the viability and antigenicity of hybrid PVs modified at neutralizing antigenic sites (NAg) I and/or NAgII.

Main Methods:

• Construction of six hybrid polioviruses (PVs) by modifying the PV type 1 (Mahoney) capsid.
• Genetic modification focused on neutralizing antigenic sites (NAg) I and NAgII to incorporate type 2 and type 3 determinants.
• Assessment of hybrid PV viability, growth characteristics, and antigenic properties through serological assays.

Main Results:

• All constructed hybrid PVs were viable but exhibited impaired growth compared to wild-type PV1 (Mahoney).
• Hybrids expressing both type 2 and type 3 NAgI determinants showed type 2 antigenicity but not type 3, alongside inherent type 1 antigenicity.
• Hybrids with combined type 2 NAgI and type 3 NAgII determinants (or vice versa) displayed characteristics of all three serotypes, though NAgII determinant expression was weak.

Conclusions:

• It is feasible to engineer viable hybrid polioviruses (PVs) with modifications at both NAgI and NAgII.
• Such hybrid PVs can simultaneously express antigenic determinants from multiple poliovirus serotypes.
• These findings offer a potential platform for developing novel poliovirus vaccines with broader serotype coverage.